Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Inactivation of the human immunodeficiency viruses (HIV‐1 and HIV‐2) during the manufacturing of placental albumin and gammaglobulins

Inactivation of the human immunodeficiency viruses (HIV‐1 and HIV‐2) during the manufacturing of... A laboratory study was undertaken to verify the elimination and/or inactivation of the human immunodeficiency viruses HIV‐1 and HIV‐2 during the manufacture of placental albumin and the gammaglobulins Gamma 16 and Veinoglobuline. Nine steps of the process were selected for study. Samples of current production batches were taken at these different stages and a known quantity of virus was added. Each sample was then processed according to the production schedule for the corresponding step, and the residual viral activity was measured. In eight of nine steps, a complete viral clearance was achieved. Estimation of the cumulative infectivity reduction due to these nine steps is in the following range: >12 to 16 log10 HIV‐1 and >17 to 19 log10 HIV‐2 for Gamma 16, >9 to 13 log10 HIV‐1 and >13 to 15 log10 HIV‐2 for Veinoglobuline, and >19.7 log10 HIV‐1 and >24 log10 HIV‐2 for albumin. As many other purification steps were not included in this study, the real infectivity reduction capacity for the whole process probably exceeds these values. Nevertheless, the levels of inactivation measured clearly document a rigorous fractionation process that has a high assurance of killing or eliminating all contaminating virus. TRANSFUSION 1989;29:629–634. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

Inactivation of the human immunodeficiency viruses (HIV‐1 and HIV‐2) during the manufacturing of placental albumin and gammaglobulins

Transfusion , Volume 29 (7) – Sep 1, 1989

Loading next page...
 
/lp/wiley/inactivation-of-the-human-immunodeficiency-viruses-hiv-1-and-hiv-2-b7JR79pSPc

References (30)

Publisher
Wiley
Copyright
1989 AABB
ISSN
0041-1132
eISSN
1537-2995
DOI
10.1046/j.1537-2995.1989.29789369683.x
Publisher site
See Article on Publisher Site

Abstract

A laboratory study was undertaken to verify the elimination and/or inactivation of the human immunodeficiency viruses HIV‐1 and HIV‐2 during the manufacture of placental albumin and the gammaglobulins Gamma 16 and Veinoglobuline. Nine steps of the process were selected for study. Samples of current production batches were taken at these different stages and a known quantity of virus was added. Each sample was then processed according to the production schedule for the corresponding step, and the residual viral activity was measured. In eight of nine steps, a complete viral clearance was achieved. Estimation of the cumulative infectivity reduction due to these nine steps is in the following range: >12 to 16 log10 HIV‐1 and >17 to 19 log10 HIV‐2 for Gamma 16, >9 to 13 log10 HIV‐1 and >13 to 15 log10 HIV‐2 for Veinoglobuline, and >19.7 log10 HIV‐1 and >24 log10 HIV‐2 for albumin. As many other purification steps were not included in this study, the real infectivity reduction capacity for the whole process probably exceeds these values. Nevertheless, the levels of inactivation measured clearly document a rigorous fractionation process that has a high assurance of killing or eliminating all contaminating virus. TRANSFUSION 1989;29:629–634.

Journal

TransfusionWiley

Published: Sep 1, 1989

There are no references for this article.